MD Anderson Ovarian SPORE publications – 2007
1.
Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V,
Freedman RS, Klostergaard J. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+)
human ovarian carcinoma xenografts. Neoplasia 9(6):479-86, 2007. PMID: 17603630; PMCID:
PMC1899257.
2.
Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers 23(5-6):397-410, 2007.
PMID: 18057523; PMCID: PMC3851959.
3.
Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr.
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum
mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol
106(3):490-7, 2007. PMID: 17532030; PMCID: PMC3374586.
4.
Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB,
Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer:
mission impossible? Recent Results Cancer Res 174:91-100, 2007. PMID: 17302189.
5.
Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R,
Rustin GJ, Spriggs D, Wenzel LB, Pazdur R. Clinical trial endpoints in ovarian cancer: report of an
FDA/ASCO/AACR Public Workshop. Gynecol Oncol 107(2):173-6, 2007. PMID: 17950384.
6.
Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E-associated kinase activity
predicts response to platinum-based chemotherapy. Clin Cancer Res 13(16):4800-6, 2007. PMID:
17699858.
7.
Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole
genome oligonucleotide-based array comparative genomic hybridization analysis identified
fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian
adenocarcinomas. J Clin Oncol 25(16):2281-7, 2007. PMID: 17538174.
8.
Brewer M, Ranger-Moore J, Satterfield W, Hao Z, Wang J, Brewer E, Wharton JT, Bast R, Zou C.
Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian
cancer. Front Biosci 12:2260-8, 2007. PMID: 17127462.
9.
Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell
12(2):104-7, 2007. PMID: 17692802.
10.
Champion V, Williams SD, Miller A, Reuille KM, Wagler-Ziner K, Monahan PO, Zhao Q, Gershenson D,
Cella D. Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic
Oncology Group study. Gynecol Oncol 105(3):687-94, 2007. PMID: 17355890; PMCID:
PMC1995655.
11.
Chi DS, Ramirez PT, Teitcher JB, Mironov S, Sarasohn DM, Iyer RB, Eisenhauer EL, Abu-Rustum NR,
Sonoda Y, Levine DA, Brown CL, Aghajanian C, Gershenson DM, Hoskins WJ, Hricak H, Barakat RR.
Prospective study of the correlation between postoperative computed tomography scan and
primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma
reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J
Clin Oncol 25(31):4946-51, 2007. PMID: 17971592.
12.
Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG. Immunohistochemical
overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous
carcinoma. Int J Gynecol Pathol 26(3):328-33, 2007. PMID: 17581420.
13.
Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after
treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best
response in recurrent ovarian cancer patients. Oncologist 12(1):72-8, 2007. PMID: 17227902.
14.
Coleman RL. 7th annual International Conference on Ovarian Cancer. Expert Rev Anticancer Ther
7(2):119-21, 2007. PMID: 17288523.
15.
Coleman RL. Gemcitabine plus carboplatin compared with carboplatin alone for platinumsensitive recurrent ovarian cancer. Curr Oncol Rep 9(6):469-71, 2007. PMID: 17991354.
16.
Coombes KR, Wang J, Baggerly KA. Microarrays: retracing steps. Nat Med 13(11):1276-7; author
reply 7-8, 2007. PMID: 17987014.
17.
Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective
systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105(2):404-8,
2007. PMID: 17292461.
18.
Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C. A pilot study of cisplatin, ifosfamide
and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol
105(2):399-403, 2007. PMID: 17292457.
19.
Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR.
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires
activation of the p38MAPK pathway. Int J Oncol 31(2):441-9, 2007. PMID: 17611702.
20.
Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z.
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol
Chem 282(15):11221-9, 2007. PMID: 17287208; PMCID: PMC1850976.
21.
Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent
J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, LopezBerestein G. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less
cardiotoxic. J Clin Invest 117(12):4044-54, 2007. PMID: 18060038; PMCID: PMC2104494.
22.
Frumovitz M, Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic
target in gynecologic malignancies. Gynecol Oncol 104(3):768-78, 2007. PMID: 17306693; PMCID:
PMC1851902.
23.
Gajewiak J, Tsukahara R, Tsukahara T, Fujiwara Y, Yu S, Lu Y, Murph M, Mills GB, Tigyi G, Prestwich
GD. Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling
networks coupled to the LPA2 receptor. ChemMedChem 2(12):1789-98, 2007. PMID: 17952880.
24.
Gershenson DM, Birrer M. Time for action: a "sea change" in treatment strategies for rare types
of epithelial ovarian cancer. Gynecol Oncol 106(1):1-3, 2007. PMID: 17574071.
25.
Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, Williams SD. Reproductive
and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor
survivors: a Gynecologic Oncology Group Study. J Clin Oncol 25(19):2792-7, 2007. PMID:
17602084.
26.
Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 25(20):2938-43, 2007.
PMID: 17617525.
27.
Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL,
Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, Huntsman DG, Gray JW.
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin
Cancer Res 13(19):5745-55, 2007. PMID: 17908964.
28.
Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari
AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal
adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67(22):10976-83, 2007.
PMID: 18006843.
29.
Hara F, Samuel S, Liu J, Rosen D, Langley RR, Naora H. A homeobox gene related to Drosophila
distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial
growth factor and fibroblast growth factor-2. Am J Pathol 170(5):1594-606, 2007. PMID: 17456765;
PMCID: PMC1854954.
30.
Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM,
Birch R, Henderson IC, Kundra V, Mills GB. Pharmacodynamic markers of perifosine efficacy. Clin
Cancer Res 13(24):7421-31, 2007. PMID: 18094426.
31.
Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of
protein lysate arrays. Bioinformatics 23(15):1986-94, 2007. PMID: 17599930.
32.
Ishiyama S, Matsueda S, Jones LA, Efferson C, Celestino J, Schmandt R, Ioannides CG, Tsuda N,
Chang DZ. Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells
in ovarian ascites. Int J Oncol 30(4):889-98, 2007. PMID: 17332928.
33.
Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N,
Terakawa N, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a
potential treatment strategy. Mol Cancer Ther 6(1):227-35, 2007. PMID: 17218636.
34.
Kamat AA, Kim TJ, Landen CN, Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM,
Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances
the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67(1):281-8, 2007. PMID:
17210709.
35.
Kavanagh JJ. Intraperitoneal chemotherapy in the treatment of ovarian cancer. J Surg Oncol
96(7):541-2, 2007. PMID: 17654524.
36.
Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth
WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Antitumor and antivascular
effects of AVE8062 in ovarian carcinoma. Cancer Res 67(19):9337-45, 2007. PMID: 17909042.
37.
Komar CM, Zacharachis-Jutz F, Cretekos CJ, Behringer RR, Rasweiler JJt. Polarized ovaries of the
long-tongued bat, Glossophaga soricina: a novel model for studying ovarian development,
folliculogenesis, and ovulation. Anat Rec (Hoboken) 290(11):1439-48, 2007. PMID: 17929278.
38.
Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M,
Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS. The receptor tyrosine kinase EphB4 is
overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J
Cancer 96(7):1083-91, 2007. PMID: 17353927; PMCID: PMC2360128.
39.
Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY,
Herzog TJ. Society of Gynecologic Oncologists Education Committee statement on risk
assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107(2):159-62,
2007. PMID: 17950381.
40.
Landen CN, Jr, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB,
Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW,
Sood AK. Neuroendocrine modulation of signal transducer and activator of transcription-3 in
ovarian cancer. Cancer Res 67(21):10389-96, 2007. PMID: 17974982.
41.
Landen CN, Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC,
Gershenson DM, Brinkley WR, Sood AK. Overexpression of the centrosomal protein Aurora-A
kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res
13(14):4098-104, 2007. PMID: 17634535.
42.
Li P, Maines-Bandiera S, Kuo WL, Guan Y, Sun Y, Hills M, Huang G, Collins CC, Leung PC, Gray JW,
Auersperg N. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic
progression. Int J Cancer 120(9):1863-73, 2007. PMID: 17266044.
43.
Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ. Pegylated liposomal doxorubicin
treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol
106(2):375-80, 2007. PMID: 17512575.
44.
Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy
in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 17(4):739-63, 2007.
PMID: 17309673.
45.
Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch
MS, Sood AK. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer
109(2):332-40, 2007. PMID: 17154180.
46.
Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA,
Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK. Curcumin inhibits tumor growth and
angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer
Res 13(11):3423-30, 2007. PMID: 17545551.
47.
Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB,
Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated
endothelial cells from invasive ovarian carcinoma. Cancer Res 67(4):1757-68, 2007. PMID:
17308118.
48.
Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY,
Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and
pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 13(14):4209-17, 2007.
PMID: 17634550.
49.
Merritt WM, Sood AK. Markers of angiogenesis in ovarian cancer. Dis Markers 23(5-6):419-31,
2007. PMID: 18057525; PMCID: PMC3850853.
50.
Milam MR, Sood AK, King S, Bassett RL, Jr, Lu KH, Slomovitz BM, Coleman RL, Ramirez PT.
Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol
109(3):641-6, 2007. PMID: 17329515.
51.
Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian
cancer by genomic approaches. Adv Cancer Res 96:1-22, 2007. PMID: 17161674.
52.
Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK.
Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5-6):367-76, 2007. PMID:
18057520; PMCID: PMC3851194.
53.
Moore RG, Bast RC Jr. How do you distinguish a malignant pelvic mass from a benign pelvic
mass? Imaging, biomarkers, or none of the above. J Clin Oncol 25(27):4159-61, 2007. PMID:
17698803.
54.
Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills G. Liquid
chromatography mass spectrometry for quantifying plasma lysophospholipids: potential
biomarkers for cancer diagnosis. Methods Enzymol 433:1-25, 2007. PMID: 17954226.
55.
Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D,
Gray JW, Mills GB. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is
associated with favorable patient prognosis in ovarian cancer. Cancer Res 67(7):3074-84, 2007.
PMID: 17409414.
56.
Nanjundan M, Zhang F, Schmandt R, Smith-McCune K, Mills GB. Identification of a novel splice
variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive
functions. Oncogene 26(18):2574-84, 2007. PMID: 17072347.
57.
Naora H. The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms.
Expert Rev Mol Med 9(13):1-12, 2007. PMID: 17477890.
58.
Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf
SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate
interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent
mechanism. J Biol Chem 282(41):29919-26, 2007. PMID: 17716980.
59.
Rodabaugh KJ, Mhawech-Fauceglia P, Groth J, Lele S, Sood AK. Prostate-derived Ets factor is
overexpressed in serous epithelial ovarian tumors. Int J Gynecol Pathol 26(1):10-5, 2007. PMID:
17197890.
60.
Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, Follen M, Wu X. Moving toward
individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian
cancer patients. Gynecol Oncol 107(1 Suppl 1):S223-9, 2007. PMID: 17825393.
61.
Saldivar JS, Wu X, Follen M, Gershenson D. Nucleotide excision repair pathway review I:
implications in ovarian cancer and platinum sensitivity. Gynecol Oncol 107(1 Suppl 1):S56-71,
2007. PMID: 17884153.
62.
Saucier JM, Yu J, Gaikwad A, Coleman RL, Wolf JK, Smith JA. Determination of the optimal
combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude
mouse model. J Oncol Pharm Pract 13(1):39-45, 2007. PMID: 17621566.
63.
Shih Ie M, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Muller-Holzner E, Gastl G, Zhang Z,
Diamandis EP. Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol 105(2):501-7,
2007. PMID: 17303231.
64.
Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva
EG, Gershenson DM. Comparison of the clinical behavior of newly diagnosed stages II-IV lowgrade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant
potential that recur as low-grade serous carcinoma. Gynecol Oncol 105(3):625-9, 2007. PMID:
17320156.
65.
Song J, Shih Ie M, Salani R, Chan DW, Zhang Z. Annexin XI is associated with cisplatin resistance
and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 13(22 Pt 1):6842-9,
2007. PMID: 17982121.
66.
Song Y, Wilkins P, Hu W, Murthy KS, Chen J, Lee Z, Oyesanya R, Wu J, Barbour SE, Fang X.
Inhibition of calcium-independent phospholipase A2 suppresses proliferation and
tumorigenicity of ovarian carcinoma cells. Biochem J 406(3):427-36, 2007. PMID: 17555408;
PMCID: PMC2049037.
67.
Spannuth WA, Thaker PH, Sood AK. Concomitant BRCA1 and BRCA2 gene mutations in an
Ashkenazi Jewish woman with primary breast and ovarian cancer. Am J Obstet Gynecol
196(4):e6-9, 2007. PMID: 17403394.
68.
Stilwell JL, Guan Y, Neve RM, Gray JW. Systems biology in cancer research: genomics to
cellomics. Methods Mol Biol 356:353-65, 2007. PMID: 16988415; PMCID: PMC2733877.
69.
Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell
Cycle 6(4):430-3, 2007. PMID: 17312398.
70.
Wang-Johanning F, Huang M, Liu J, Rycaj K, Plummer JB, Barnhart KF, Satterfield WC, Johanning GL.
Sheep stromal-epithelial cell interactions and ovarian tumor progression. Int J Cancer
121(10):2346-54, 2007. PMID: 17657741.
71.
Wang-Johanning F, Liu J, Rycaj K, Huang M, Tsai K, Rosen DG, Chen DT, Lu DW, Barnhart KF,
Johanning GL. Expression of multiple human endogenous retrovirus surface envelope proteins
in ovarian cancer. Int J Cancer 120(1):81-90, 2007. PMID: 17013901.
72.
Wong KK, Gershenson D. The continuum of serous tumors of low malignant potential and lowgrade serous carcinomas of the ovary. Dis Markers 23(5-6):377-87, 2007. PMID: 18057521; PMCID:
PMC3850577.
73.
Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT,
Silva EG, Gershenson DM. Significantly greater expression of ER, PR, and ECAD in advancedstage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J
Gynecol Pathol 26(4):404-9, 2007. PMID: 17885490.
74.
Yang G, Rosen DG, Colacino JA, Mercado-Uribe I, Liu J. Disruption of the retinoblastoma pathway
by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to
immortalization of human ovarian surface epithelial cells. Oncogene 26(10):1492-8, 2007. PMID:
16953228.
75.
Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC Jr, Zhou C, Liu J. Knockdown
of p53 combined with expression of the catalytic subunit of telomerase is sufficient to
immortalize primary human ovarian surface epithelial cells. Carcinogenesis 28(1):174-82, 2007.
PMID: 16829690.
76.
Young TW, Mei FC, Rosen DG, Yang G, Li N, Liu J, Cheng X. Up-regulation of tumor susceptibility
gene 101 protein in ovarian carcinomas revealed by proteomics analyses. Mol Cell Proteomics
6(2):294-304, 2007. PMID: 17110434.
77.
Young TW, Rosen DG, Mei FC, Li N, Liu J, Wang XF, Cheng X. Up-regulation of tumor
susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in
ovarian cancer. Clin Cancer Res 13(13):3848-54, 2007. PMID: 17606716.
78.
Zhang Z, Singh M, Davidson S, Rosen DG, Yang G, Liu J. Activation of BTAK expression in primary
ovarian surface epithelial cells of prophylactic ovaries. Mod Pathol 20(10):1078-84, 2007. PMID:
17673924.
79.
Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG,
Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr. Combining multiple serum tumor markers
improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 107(3):526-31, 2007. PMID:
17920110; PMCID: PMC2171045.
80.
Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int J Gynecol
Cancer 17(2):325-38, 2007. PMID: 17362310.